Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Significant Decline in Short Interest

Gossamer Bio, Inc. (NASDAQ:GOSS) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 948,623 shares, a decrease of 98.9% from the August 31st total of 82,633,317 shares. Currently, 33.7% of the shares of the stock are short sold. Based on an average trading volume of 186,993 shares, the short-interest ratio is currently 5.1 days.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research report on Tuesday, July 28th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Gossamer Bio currently has an average rating of “Hold” and an average target price of $256.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio in the second quarter valued at approximately $2,467,000. Kalehua Capital Management LLC acquired a new position in Gossamer Bio during the first quarter worth $3,363,000. ARCH Venture Management LLC purchased a new stake in Gossamer Bio in the 2nd quarter valued at $1,326,004. BlackRock Inc. purchased a new stake in Gossamer Bio in the 2nd quarter valued at $1,262,000. Finally, Corient Private Wealth LP increased its stake in shares of Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after acquiring an additional 1,647,315 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: Gossamer Bio submitted a New Drug Application to the U.S. Food and Drug Administration for seralutinib, its lead candidate for pulmonary arterial hypertension. The filing represents a major development milestone and could improve the company’s long-term commercial prospects if accepted and ultimately approved. Gossamer Bio Submits New Drug Application to the FDA
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and raised several longer-term EPS forecasts, including estimates for 2027 through 2029. The revisions suggest the analyst expects improving financial performance as seralutinib advances toward potential commercialization. Gossamer Bio analyst estimates
• Neutral Sentiment: Reports on September short interest are contradictory: one cites a sharp decline to 948,623 shares, while another reports zero shares short. The figures may reflect a reporting or corporate-action issue, so investors should verify the data before interpreting it as evidence of covering or short-squeeze potential.
• Negative Sentiment: Despite the NDA milestone, reports indicated that Gossamer Bio’s stock fell following the FDA filing, suggesting a possible “sell-the-news” reaction or investor disappointment with the filing’s near-term impact. The company remains dependent on regulatory progress and has yet to generate commercial revenue. Gossamer Bio stock falls after FDA filing
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast, as well as estimates for the fourth quarter of 2026 and first quarter of 2027. Although the firm remains bullish overall, the revisions highlight continued substantial losses and financing risk while Gossamer funds development.

Gossamer Bio Price Performance

GOSS traded down $0.06 on Thursday, reaching $10.93. 236,070 shares of the company’s stock were exchanged, compared to its average volume of 210,656. Gossamer Bio has a twelve month low of $9.10 and a twelve month high of $309.60. The stock has a market cap of $32.02 million, a PE ratio of -0.20 and a beta of 2.00. The stock’s fifty day moving average price is $13.02 and its 200-day moving average price is $19.53.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.